Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Lancet (London, England)·2026
Same author

Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.

Eye (London, England)·2026
Same author

Injected Eye, Fellow Eye and Systemic Pharmacokinetic Modeling of Intravitreally Administered Bevacizumab.

Molecular pharmaceutics·2026
Same author

High-throughput PBK modelling for dermal exposure: a pragmatic approach to predict systemic pharmacokinetics.

Archives of toxicology·2026
Same author

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

CPT: pharmacometrics & systems pharmacology·2026

Related Experiment Video

Updated: May 26, 2026

Multiscale Sampling of a Heterogeneous Water/Metal Catalyst Interface using Density Functional Theory and Force-Field Molecular Dynamics
10:52

Multiscale Sampling of a Heterogeneous Water/Metal Catalyst Interface using Density Functional Theory and Force-Field Molecular Dynamics

Published on: April 12, 2019

Multiscale mechanistic modeling in pharmaceutical research and development.

Lars Kuepfer1, Jörg Lippert, Thomas Eissing

  • 1Systems Biology and Computational Solutions, Bayer Technology Services GmbH, Building 9115, 51368 Leverkusen, Germany. lars.kuepfer@bayer.com

Advances in Experimental Medicine and Biology
|December 14, 2011
PubMed
Summary

Computational modeling and simulation can improve drug development decision-making by integrating complex biological data. This approach helps predict clinical trial success, reducing costly failures in pharmaceutical research and development.

More Related Videos

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies
07:31

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies

Published on: September 1, 2023

Related Experiment Videos

Last Updated: May 26, 2026

Multiscale Sampling of a Heterogeneous Water/Metal Catalyst Interface using Density Functional Theory and Force-Field Molecular Dynamics
10:52

Multiscale Sampling of a Heterogeneous Water/Metal Catalyst Interface using Density Functional Theory and Force-Field Molecular Dynamics

Published on: April 12, 2019

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies
07:31

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies

Published on: September 1, 2023

Area of Science:

  • Pharmacology and Drug Development
  • Computational Biology
  • Biomedical Engineering

Background:

  • Drug development faces significant costs due to project failures, particularly late-stage clinical trial setbacks.
  • High costs of clinical trials necessitate better prediction of drug efficacy and safety to guide investment.
  • Human cognitive limitations hinder the effective integration of vast biological data for predicting development success.

Purpose of the Study:

  • To provide an overview of modeling and simulation in pharmaceutical R&D.
  • To explore recent advancements in mechanistic modeling for drug development.
  • To demonstrate the application of integrative multiscale modeling in clinical oncology.

Main Methods:

  • Review of current modeling and simulation approaches in pharmaceutical R&D.
  • Introduction of mechanistic modeling techniques across various biological scales.
  • Showcasing an example of multiscale modeling for therapeutic efficiency in oncology trials.

Main Results:

  • Computational models offer improved rationalization for decision-making in pharmaceutical R&D.
  • Mechanistic modeling provides a framework for integrating diverse biological data.
  • Integrative multiscale modeling can enhance the prediction of therapeutic efficiency.

Conclusions:

  • Modeling and simulation are crucial for optimizing pharmaceutical R&D investments.
  • Mechanistic and multiscale modeling represent promising future directions for drug development.
  • These approaches enhance patient safety and maximize medical benefit by improving prediction accuracy.